Back to top
more

Atea Pharmaceuticals (AVIR)

(Real Time Quote from BATS)

$3.28 USD

3.28
165,365

+0.05 (1.55%)

Updated Jul 3, 2024 02:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Ocugen (OCGN) Stock Has More Than Tripled This Year

by Zacks Equity Research

Ocugen's (OCGN) stock rides on the company's collaboration with India's Bharat Biotech to co-develop and commercialize the latter's COVID-19 vaccine, COVAXIN, for the U.S. market.

Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year

by Zacks Equity Research

Entera Bio's (ENTX) stock price is being driven by encouraging data from phase II study on EB613, its investigational orally delivered treatment for osteoporosis

Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC

by Zacks Equity Research

Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.

Atea Pharmaceuticals (AVIR) Enters Oversold Territory

by Zacks Equity Research

Atea Pharmaceuticals (AVIR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

Reata's (RETA) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Reata (RETA) reports mixed first-quarter results wherein earnings beat estimates but sales miss the same. Stock rises.

Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.

Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline. The company launches its third DMD drug, Vyondys 53, in quarter.

Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) beats Q1 bottom-line estimates. The company progresses with the development of its key pipeline candidate, etrasimod.

Clovis (CLVS) Q1 Earnings Beat, COVID-19 Hurts Rubraca Sales

by Zacks Equity Research

Clovis (CLVS) reports lower-than-expected loss for first-quarter 2021. Lower new patient start amid COVID-19 hurts U.S. sales of Rubraca. Stock up.

Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances

by Zacks Equity Research

Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.

Ultragenyx (RARE) Q1 Loss Narrows Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx Pharmaceutical (RARE) Q1 sales increase year over year while loss narrows

Repligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View

by Zacks Equity Research

Repligen (RGEN) reports encouraging first-quarter results with sales and earnings beating estimates. The company also raises its guidance for 2021. Stock up.

Atea Pharmaceuticals (AVIR) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Atea Pharmaceuticals (AVIR) has been struggling lately, but the selling pressure may be coming to an end soon

Atea Pharmaceuticals (AVIR) Is in Oversold Territory: What's Next?

by Zacks Equity Research

Atea Pharmaceuticals (AVIR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat

by Zacks Equity Research

Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.

Tandem (TNDM) Grows on Abbott, Dexcom Pacts Amid COVID-19 Woes

by Zacks Equity Research

Tandem Diabetes (TNDM) is expects t:sport to be a major growth catalyst for 2022.

Illumina's (ILMN) Expanded NIPT Coverage Study Outcome Favorable

by Zacks Equity Research

Illumina's (ILMN) coverage for pregnant women under the age of 35 will provide access of NIPT to thousands of women with minimal financial impact.

Illumina (ILMN) NGS-Based Platform Approved for Use in Russia

by Zacks Equity Research

Illumina and R-Pharm's in-vitro diagnostics platform registration will drive the expansion of Next Generation Sequencing-based clinical diagnostics across Russia.

QIAGEN (QGEN) Unveils Digital Platform for Syndromic Testing

by Zacks Equity Research

QIAGEN's (QGEN) QIAsphere cloud-based platform will enhance QIAstat-Dx's potential by offering remote services round the clock to improve testing continuity.

Sweta Killa headshot

Nasdaq Turns Red YTD: 5 Top-Ranked Stocks Up More Than 50%

by Sweta Killa

As the Nasdaq eroded all the gains made this year and turned red due to the tech sell-off, there are still some stocks that have gained more than 50% so far this year.

QIAGEN (QGEN) Launches QIAcube Connect MDx Platform Globally

by Zacks Equity Research

QIAGEN's (QGEN) QIAcube Connect MDx platform can be used with more than 140 standard protocols and it ensures complete consistency of the purification of multiple sample types.

Medtronic's (MDT) HVAD Pump Kit Recall Classified as Class I

by Zacks Equity Research

The latest back-to-back incidents will, undoubtedly, create a major drag in Medtronic's (MDT) VAD performance.

Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances

by Zacks Equity Research

Allogene (ALLO) reports no revenues for the fourth quarter of 2020.

Bayer's (BAYRY) Q4 Earnings Match Estimates, Sales Miss

by Zacks Equity Research

Bayer (BAYRY) reports in-line earnings and misses sales estimates in the fourth quarter of 2020.

Horizon's (HZNP) Shares Rise on Q4 Earnings & Sales Beat

by Zacks Equity Research

Horizon (HZNP) beats earnings and sales estimates in the fourth quarter of 2020.